TechnoPhage — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $11.7M

Overview

TechnoPhage is a clinical-stage biotech company developing novel therapeutics using a multi-platform approach centered on bacteriophage technology and biologics like recombinant single-domain antibodies. Its pipeline includes programs in infection, neurosciences, and ophthalmology, with a lead candidate, TP-102, having completed a Phase 2b trial. The company is privately held, pre-revenue, and has received national recognition in Portugal for its competitiveness and excellence, positioning it for potential Phase 3 development and partnerships.

InfectionNeurosciencesOphthalmology

Technology Platform

Multi-platform approach including bacteriophage-based therapies, recombinant single-domain antibodies (sdAbs) biologics, and drug repositioning strategies supported by in vivo models.

Funding History

2

Total raised:$11.7M

Series A$8.5MPortugal VenturesSep 15, 2020

Grant$3.2MEuropean Innovation CouncilJun 15, 2019

Opportunities

The growing crisis of antimicrobial resistance presents a significant opportunity for its bacteriophage platform.

The versatility of its single-domain antibody and drug repositioning platforms allows for expansion into multiple high-value therapeutic areas within neuroscience and ophthalmology.

Risk Factors

High clinical development risk associated with advancing TP-102 into Phase 3.

Financial risk due to pre-revenue status and the capital-intensive nature of late-stage trials.

Regulatory uncertainty, particularly for novel modalities like phage therapy.

Competitive Landscape

Competes with large pharmaceutical companies and numerous biotechs in infection, neuroscience, and ophthalmology. Its phage technology faces competition from other microbiome and phage-focused firms, while its sdAb platform competes with companies developing next-generation antibody fragments and biologics.

More companies in Biologics / Biosimilars →More companies in Portugal →